Introduction: Hyperuricemia (HUA) is associated with metabolic syndrome (MetS) in the general population. Military individuals who perform high-intensity physical training might have lower rates of MetS. The present study aimed to investigate whether HUA might be associated with the prevalence of MetS in military individuals.
Material And Methods: We retrospectively collected data from the annual military exam and randomly selected a single unit to represent the overall study population. The study population consisted of 460 military individuals between January 2016 and December 2016. We divided this cohort into the HUA group and the normouricemic group. Hyperuricemia is defined as a serum uric acid level of 7 mg/dL or more in men or 6 mg/dL or more in women.
Results: The cohort consisted of 460 individuals with a mean age of 35.9 yr old; 80% were male and 15% were diagnosed with MetS between January 1, 2016 and December 31, 2016. The prevalence of MetS was greater in the HUA group than in the normouricemic group (32.5% vs. 8.8%, p < 0.001). HUA was independently associated with the prevalent MetS after adjusting for age, gender, creatinine, alanine transaminase, and hemoglobin (adjusted OR: 4.305, 95% CI: 2.370-7.818, p < 0.001). Given that the cohort was predominantly male, we divided the cohort into men and women for a subgroup analysis. A significant association was found in men but not in women (adjusted OR: 3.59 95% CI: 1.905-6.765, p < 0.001 for men and adjusted OR: 16.7 95% CI: 0.295-946, p = 0.172 for women, respectively).
Conclusion: Hyperuricemia was independently associated with the prevalence of metabolic syndrome in a military cohort from Taiwan. Future studies should look at whether hyperuricemia in individuals without metabolic syndrome can predict the future onset of metabolic syndrome.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/milmed/usy097 | DOI Listing |
PLoS One
January 2025
Specialist in Family and Community Medicine, Milladoiro Health Centre, Health Area of Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Purpose: To determine the relationship between self-reported physical activity and the components of premorbid metabolic syndrome in patients treated in primary care according to sex.
Methods: Cross-sectional descriptive study conducted on a sample of 2,359 patients without cardiovascular disease or diabetes, included in the cohort of the IBERICAN study. Using ANOVA models and adjusting for age, economic status, employment situation, level of education, adherence to a Mediterranean diet, tobacco use and alcohol consumption, we estimated the association of the variables blood pressure, triglycerides, HDL cholesterol, blood glucose and waist circumference with the self-reported level of physical activity (sedentary, moderate, high, very high).
Diabetes
January 2025
Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
PPARγ is the pharmacological target of thiazolidinediones (TZDs), potent insulin sensitizers that prevent metabolic disease morbidity but are accompanied by side effects such as weight gain, in part due to non-physiological transcriptional agonism. Using high throughput genome engineering, we targeted nonsense mutations to every exon of PPARG, finding an ATG in Exon 2 (chr3:12381414, CCDS2609 c.A403) that functions as an alternative translational start site.
View Article and Find Full Text PDFBJU Int
January 2025
Department of Urology, Mayo Clinic Arizona, Phoenix, AZ, USA.
Objectives: To compare postoperative complication rates of patients with metabolic syndrome (MetS) with patients without MetS after holmium laser enucleation of the prostate (HoLEP) for management of benign prostatic hyperplasia (BPH).
Patients And Methods: We retrospectively reviewed patients aged >40 years who underwent HoLEP at our institution from 2007 to 2022. Criteria for MetS were diagnoses of at least three of the following: diabetes mellitus, hypertension, hyperlipidaemia, or obesity (body mass index ≥30 kg/m).
Rev Med Chil
September 2024
Hospital de Niños Dr. Roberto del Río, Santiago, Chile.
Hereditary tyrosinemia type 1 (HT-1) is an inborn error of metabolism caused by a defect in tyrosine (tyr) degradation. This defect results in the accumulation of succinylacetone (SA), causing liver failure with a high risk of hepatocarcinoma and kidney injury, leading in turn to Fanconi syndrome with urine loss of phosphate and secondary hypophosphatemic rickets (HR). HT-1 diagnosis is usually made in infants with acute or chronic liver failure or by neonatal screening programs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!